[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
    "url": "https://finnhub.io/api/news?id=66b417b8404a82f3f931c48f50de5af21d2e9613a9f37532b8f91c21671a95a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771880489,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 139187961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S",
      "url": "https://finnhub.io/api/news?id=66b417b8404a82f3f931c48f50de5af21d2e9613a9f37532b8f91c21671a95a7"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays started coverage of Merck & Co., Inc. (NYSE:MRK) with an Overweight rating. It set a $140 price target on the stock. The firm said the company’s 2026 will bring “first-in-class” launches and important […]",
    "url": "https://finnhub.io/api/news?id=69d95b917a3b34f53329eab4e685597bc41b6d205420b451653786ec972db4cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771870365,
      "headline": "Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation",
      "id": 139187281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Barclays started coverage of Merck & Co., Inc. (NYSE:MRK) with an Overweight rating. It set a $140 price target on the stock. The firm said the company’s 2026 will bring “first-in-class” launches and important […]",
      "url": "https://finnhub.io/api/news?id=69d95b917a3b34f53329eab4e685597bc41b6d205420b451653786ec972db4cc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Next-Generation Obesity Shot Falls Short of Lilly Rival",
    "summary": "Novo Nordisk's next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company's attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo's CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly's tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda.",
    "url": "https://finnhub.io/api/news?id=45a57c4f981a31897cb98052d798fff89c70f59c764289c9ff6bafa9e26ec574",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771868662,
      "headline": "Novo Next-Generation Obesity Shot Falls Short of Lilly Rival",
      "id": 139187237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Novo Nordisk's next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company's attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo's CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly's tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda.",
      "url": "https://finnhub.io/api/news?id=45a57c4f981a31897cb98052d798fff89c70f59c764289c9ff6bafa9e26ec574"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
    "summary": "? Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ↘️ Novo Nordisk (NVO), (DK:NOVO.",
    "url": "https://finnhub.io/api/news?id=6adc7ab400ce9225ffacd064418fc9532cca6d1c1c3066289ae6b99aad5741eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771857667,
      "headline": "Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead",
      "id": 139185136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "? Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. ↘️ Novo Nordisk (NVO), (DK:NOVO.",
      "url": "https://finnhub.io/api/news?id=6adc7ab400ce9225ffacd064418fc9532cca6d1c1c3066289ae6b99aad5741eb"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
    "url": "https://finnhub.io/api/news?id=635e84af3373b485c764a864bbc9d602792ef4c29d307c64e897db8ce35169d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771854368,
      "headline": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
      "id": 139183628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
      "url": "https://finnhub.io/api/news?id=635e84af3373b485c764a864bbc9d602792ef4c29d307c64e897db8ce35169d2"
    }
  },
  {
    "ts": null,
    "headline": "Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs",
    "summary": "Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent...",
    "url": "https://finnhub.io/api/news?id=48a97534c5eec9c6b807d83bd6d4086f605d4219068ee35afd76a33665bf023c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771852980,
      "headline": "Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs",
      "id": 139183723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent...",
      "url": "https://finnhub.io/api/news?id=48a97534c5eec9c6b807d83bd6d4086f605d4219068ee35afd76a33665bf023c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Revamps Pharmaceutical Unit, Creating Separate Cancer Business",
    "summary": "The drugmaker is reorganizing to bolster product launches ahead its cancer drug Keytruda’s patent loss.",
    "url": "https://finnhub.io/api/news?id=bf14ddd120aad2825df21fb5d8040094963aa5001d347908bb55edfd5edd16d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771850700,
      "headline": "Merck Revamps Pharmaceutical Unit, Creating Separate Cancer Business",
      "id": 139186417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The drugmaker is reorganizing to bolster product launches ahead its cancer drug Keytruda’s patent loss.",
      "url": "https://finnhub.io/api/news?id=bf14ddd120aad2825df21fb5d8040094963aa5001d347908bb55edfd5edd16d9"
    }
  },
  {
    "ts": null,
    "headline": "Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.",
    "summary": "The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.",
    "url": "https://finnhub.io/api/news?id=9d424fee787ee801962245d0e46fa389f2b2b0924af04949852cf40409723d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771850280,
      "headline": "Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.",
      "id": 139183724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.",
      "url": "https://finnhub.io/api/news?id=9d424fee787ee801962245d0e46fa389f2b2b0924af04949852cf40409723d51"
    }
  },
  {
    "ts": null,
    "headline": "Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
    "summary": "RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
    "url": "https://finnhub.io/api/news?id=d835a0f0314259f7f4cdc8fa7b88c7404f0153c3a50100f463e10e7a0dccfb3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771847100,
      "headline": "Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
      "id": 139183063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
      "url": "https://finnhub.io/api/news?id=d835a0f0314259f7f4cdc8fa7b88c7404f0153c3a50100f463e10e7a0dccfb3c"
    }
  },
  {
    "ts": null,
    "headline": "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports",
    "summary": "Feb 23 () - Merck is splitting its human-health business into two ‌divisions to offset pressures ‌related to the loss of patent for its ​top-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including ‌Keytruda, while ⁠the other will sell its non-cancer products, the report ⁠said.",
    "url": "https://finnhub.io/api/news?id=8949053bde9c09936122b21ae166f1dee7ea3047f315ae78970781674a01479c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771846829,
      "headline": "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports",
      "id": 139183064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Feb 23 () - Merck is splitting its human-health business into two ‌divisions to offset pressures ‌related to the loss of patent for its ​top-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including ‌Keytruda, while ⁠the other will sell its non-cancer products, the report ⁠said.",
      "url": "https://finnhub.io/api/news?id=8949053bde9c09936122b21ae166f1dee7ea3047f315ae78970781674a01479c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
    "summary": "? American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
    "url": "https://finnhub.io/api/news?id=6348325e68d87034b6baf1aa52bd9b839aeee05cf344928def011007645b619d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771841184,
      "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
      "id": 139183030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "? American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
      "url": "https://finnhub.io/api/news?id=6348325e68d87034b6baf1aa52bd9b839aeee05cf344928def011007645b619d"
    }
  },
  {
    "ts": null,
    "headline": "Merck Creates Separate Cancer Business as Sales Pressure Looms",
    "summary": "The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.",
    "url": "https://finnhub.io/api/news?id=e894f94911bc95a4dc444bf4580ce25b4c5e30e47b2ead7718c32109673c5b51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771844400,
      "headline": "Merck Creates Separate Cancer Business as Sales Pressure Looms",
      "id": 139183065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.",
      "url": "https://finnhub.io/api/news?id=e894f94911bc95a4dc444bf4580ce25b4c5e30e47b2ead7718c32109673c5b51"
    }
  },
  {
    "ts": null,
    "headline": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
    "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
    "url": "https://finnhub.io/api/news?id=041d13dea2754ba945a74cafd7981a11b86b2a1d3e81b26d5fcdebf806f11a3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771837740,
      "headline": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
      "id": 139182333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
      "url": "https://finnhub.io/api/news?id=041d13dea2754ba945a74cafd7981a11b86b2a1d3e81b26d5fcdebf806f11a3f"
    }
  },
  {
    "ts": null,
    "headline": "Merck to split cancer, specialty drug businesses in leadership shakeup",
    "summary": "Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.",
    "url": "https://finnhub.io/api/news?id=6167df0107375033051e6b9d5325514c890a5b59fe6b8f6781390456bd0221cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771835908,
      "headline": "Merck to split cancer, specialty drug businesses in leadership shakeup",
      "id": 139185191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.",
      "url": "https://finnhub.io/api/news?id=6167df0107375033051e6b9d5325514c890a5b59fe6b8f6781390456bd0221cb"
    }
  },
  {
    "ts": null,
    "headline": "Merck Is Organizing Its Human Health Business Into An Oncology Business Unit And A Specialty, Pharma & Infectious Diseases Business Unit",
    "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse",
    "url": "https://finnhub.io/api/news?id=00528556cf66bac8b453ead591c0704cfea158d8262560a8eb782e5b9c45de36",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771832927,
      "headline": "Merck Is Organizing Its Human Health Business Into An Oncology Business Unit And A Specialty, Pharma & Infectious Diseases Business Unit",
      "id": 139184120,
      "image": "",
      "related": "MRK",
      "source": "Benzinga",
      "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse",
      "url": "https://finnhub.io/api/news?id=00528556cf66bac8b453ead591c0704cfea158d8262560a8eb782e5b9c45de36"
    }
  },
  {
    "ts": null,
    "headline": "The Wall Street Journal Reported Merck To Split Pharma Unit Into Two Businesses; One For Oncology; One For Other Drugs",
    "summary": "The Wall Street Journal Reported Merck To Split Pharma Unit Into Two Businesses; One For Oncology; One For Other Drugs",
    "url": "https://finnhub.io/api/news?id=8821b883a9799f6549b20f58b4c7801ff6f294fb4b2993be9d2fb6278b48ec74",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771830640,
      "headline": "The Wall Street Journal Reported Merck To Split Pharma Unit Into Two Businesses; One For Oncology; One For Other Drugs",
      "id": 139184121,
      "image": "",
      "related": "MRK",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8821b883a9799f6549b20f58b4c7801ff6f294fb4b2993be9d2fb6278b48ec74"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Large Cap Value Fund Q4 2025 Portfolio Review",
    "summary": "Harbor Large Cap Value Fund Q4 2025 Portfolio Review",
    "url": "https://finnhub.io/api/news?id=be88801f6cd34ab8b8d2e34d4786cbb9eba1cfe6fc396424d3a73ea62e894da0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771823520,
      "headline": "Harbor Large Cap Value Fund Q4 2025 Portfolio Review",
      "id": 139182518,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=be88801f6cd34ab8b8d2e34d4786cbb9eba1cfe6fc396424d3a73ea62e894da0"
    }
  }
]